The stem cell industry is rapidly changing. To keep you in the loop, we have released new coverage of industry events. Check it out and let me know what you think?
Enrollment of First Cohort Completed with Eighth Participant Dosed in Cynata’s World First Clinical TrialAustralian stem cell company, Cynata Therapeutics Limited (ASX:CYP), announces the eighth participant has been dosed in its world first clinical trial of CYP-001 for the treatment of steroid-resistant graft-versus-host-disease (GvHD). Enrollment of the first cohort (Cohort A) is now complete. Participants in Cohort A received two CYP-001 infusions each at the lower dose level (1 million cells/kg, up to a maximum of 100 million cells per infusion).
Ncardia announces completion of €10.5M Investment RoundRecently formed by the merger of Axiogenesis and Pluriomics, Ncardia is a privately held company with operations in Europe and the U.S. that produces high-quality, fully functional human iPSC derived cardiovascular and neuronal cell types. Ncardia has announced the completion of a €10.5 million Series B financing round, led by Épimède, a Belgium venture capital firm.
Fortuna Fix Announces Series B Financing, Adding Amgen Ventures and Macnguyen Family Office as ShareholdersFortuna Fix is aiming to be the first to bring to the clinic a patient’s own neural stem cells (autologous) produced by direct reprogramming (“drNPCs”) to replace lost neuronal tissue in neurodegeneration and neurotrauma. Fortuna has announced the closing of its USD $25 million Series B financing. The proceeds will enable the company to conduct Phase I/IIa clinical trials in Parkinson’s Disease and Spinal Cord Injury. Amgen Ventures and the Macnguyen Family Office joined the company as shareholders. FDA Lifts Clinical Hold on Cellectis Phase 1 Clinical Trials with UCART123 in AML and BPDCNCellectis, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that the U.S. FDA has lifted the clinical hold, previously announced on September 4, 2017, on Phase 1 trials of Cellectis’ UCART123 product candidate in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). ISCT Webinar on Cell and Gene Therapy (CGT) Products in Japan
Have you heard of the recent regulatory changes surrounding cell and gene therapy (CGT) products in Japan? Robert Preti, PhD (General Manager of Hitachi Chemical’s Regenerative Medicine Business Sector) and Kazuchika Furuishi, PhD (Deputy General Manager) are joining Colin Novick (Managing Director at CJ PARTNERS Inc.) to discuss the challenges to consider while taking your clinical cell or gene therapy program to Japan.
Current and Future Opportunities for Stem Cell ExosomesTo operate successfully within the exosome marketplace, it is vital to assess novel opportunities for product development. There are five market segments that compose the market for stem cell exosomes, including therapeutics, diagnostic tools, research tools, cosmeceuticals, and manufacturing technologies. A leading competitor within the exosome market is Lonza, which acquired HansaBioMed Life Sciences in May 2017, while simultaneously investing in Exosomics. Cord Blood Banking Survey of U.S. Parents [2017]
It is critical for cord blood banks to understand the needs and expectations of their prospective clients. For this purpose, an electronic survey was distributed to recent and expectant parents in the United States. The survey link was distributed in Facebook groups related to pregnancy and early-child parenthood during September and October 2017, collecting a total of 111 responses. These findings can now be accessed and implemented into your cord blood bank.
Market Size Determination for the Cell Therapy CDMO Market
Among cell therapy companies, the pressure for manufacturing innovation and optimization can incentivize them to seek third-party partners who possess technical, manufacturing, and regulatory expertise, such as cell therapy contract and development manufacturing organizations (CDMOs). For this reason, this 20-page market brief defines the size of the Cell Therapy CDMO Market and provides future market projections.
It's Almost Time for Ncardia's 1st Annual Applications Workshop (Nov 29 - Dec 1)
It is almost time for Ncardia's Application Workshop, taking place at BioCampus Cologne on November 29 - December 1st, 2017. The speakers will highlight the use of human iPSC-derived products within their fields of profession, and t he demonstrations will showcase the performance of Ncardia's cells in applications such as MEA, contractile cell force measurement, impedance analysis, calcium transient measurement, and more. Are you registered to attend?
Be Great,
Cade President/CEO of BioInformant.com "1st and Only Market Research Firm to Specialize in the Stem Cell Industry"
p.s. Have stem cell news to share? Hit "reply" to this email to send it to me.
|
|
|
